Alpha Tau Medical (NASDAQ:DRTS – Get Free Report) announced its earnings results on Thursday. The company reported ($0.33) earnings per share for the quarter, missing the consensus estimate of ($0.15) by ($0.18), reports.
Alpha Tau Medical Price Performance
DRTS traded down $0.68 during trading on Thursday, reaching $11.33. The stock had a trading volume of 1,239,684 shares, compared to its average volume of 589,480. The firm has a market capitalization of $1.02 billion, a price-to-earnings ratio of -10.90 and a beta of 1.28. The company has a quick ratio of 7.79, a current ratio of 11.09 and a debt-to-equity ratio of 0.15. Alpha Tau Medical has a 1-year low of $3.43 and a 1-year high of $15.79. The stock has a 50 day moving average of $13.90 and a two-hundred day moving average of $10.99.
Insider Transactions at Alpha Tau Medical
In other news, CFO Raphi Levy sold 2,871 shares of Alpha Tau Medical stock in a transaction on Friday, August 21st. The stock was sold at an average price of $15.00, for a total transaction of $43,065.00. Following the transaction, the chief financial officer directly owned 90,180 shares in the company, valued at approximately $1,352,700. This trade represents a 3.09% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 39.50% of the company’s stock.
Wall Street Analysts Forecast Growth
DRTS has been the subject of several recent analyst reports. Zacks Research raised Alpha Tau Medical from a “strong sell” rating to a “hold” rating in a research note on Monday, November 9th. UBS Group restated a “buy” rating on shares of Alpha Tau Medical in a research note on Tuesday. Barclays upped their price objective on shares of Alpha Tau Medical from $17.00 to $30.00 and gave the stock an “overweight” rating in a report on Thursday, September 3rd. Benchmark reiterated a “buy” rating on shares of Alpha Tau Medical in a research report on Thursday, July 23rd. Finally, HC Wainwright reissued a “buy” rating and set a $16.00 target price on shares of Alpha Tau Medical in a research note on Tuesday. Seven analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Alpha Tau Medical has a consensus rating of “Moderate Buy” and an average target price of $18.20.
View Our Latest Research Report on Alpha Tau Medical
Alpha Tau Medical Company Profile
Alpha Tau Medical Ltd. is an Israel-based medical technology company developing Alpha DaRT, an investigational radiation treatment for solid tumors. The company was founded in 2016 and is headquartered in Jerusalem. Alpha DaRT uses tiny sources containing radium-224 that are placed directly inside a tumor. As the material decays, it releases alpha-emitting atoms that travel a short distance through the tumor, aiming to destroy cancer cells while limiting exposure to nearby healthy tissue. The company is conducting clinical development of Alpha DaRT for multiple types of solid tumors, with research and clinical trials in Israel and other countries, including the United States and Japan.
Recommended Stories
- Five stocks we like better than Alpha Tau Medical
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
Receive News & Ratings for Alpha Tau Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpha Tau Medical and related companies with MarketBeat.com's FREE daily email newsletter.
